Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Abortion Drugs

Ground Zero in the Right-to-Life Battle

For nearly a half-century, the towering columns rising from the steps outside the U.S. Supreme Court building have stood like a massive gravestone for the more than 63 million lives lost to abortion.

But following the Supreme Court’s reversal in June of its deadly ruling in 1973 legalizing genocide in the womb nationwide, the front-line battles to protect pre-born babies’ lives have expanded from the highest court in the land all the way to your local pharmacy.

In early January, the Federal Drug Administration (FDA) widened the distribution of the lethal drug mifepristone, also known as RU-486, by allowing pharmacies to be certified by the federal government to dispense abortifacients. Misoprostol, the second drug used in chemical abortions, is taken 24-48 hours after mifepristone. Because it is also prescribed for various other medical conditions, it has never been as restricted as mifepristone.

Continue Reading at Decision Magazine  >>

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

Ultrasound image showing the side profile of a human baby

Inside The Government Decision That Opened Up Abortion Pill Floodgates

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026
A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image